Please use this identifier to cite or link to this item:
Title: Intravitreal Bevacizumab for Refractory Pseudophakic Cystoid Macular Edema the Pan-American Collaborative Retina Study Group Results
Authors: Fernando Arevalo, J.
Maia, Mauricio [UNIFESP]
Garcia-Amaris, Rafael A.
Roca, Jose A.
Sanchez, Juan G.
Berrocal, Maria H.
Wu, Lihteh
Clin Oftalmol Ctr Caracas
Universidade Federal de São Paulo (UNIFESP)
Clin Ricardo Palma
Univ Puerto Rico
Inst Cirugia Ocular
Issue Date: 1-Aug-2009
Publisher: Elsevier B.V.
Citation: Ophthalmology. New York: Elsevier B.V., v. 116, n. 8, p. 1481-1487, 2009.
Abstract: Objective: To determine the feasibility, safety, and clinical effect of intravitreal (IVT) bevacizumab (Avastin; Genentech, Inc., San Francisco, CA) in patients with refractory cystoid macular edema (CME) after cataract surgery.Design: Interventional, retrospective, multicenter study.Participants: Thirty-six eyes of 31 patients with refractory CME after cataract surgery and with a mean age of 68.2 years (range, 67-87 years).Methods: Patients were treated with at least 1 IVT injection of 1.25 or 2.5 mg bevacizumab. Patients were followed up for 12 months.Main Outcome Measures: Best-corrected visual acuity (BCVA) and central macular thickness (CMT) by optical coherence tomography (OCT).Results: Twenty-six eyes (72.2%) demonstrated improvement of BCVA ( >= 2 Early Treatment Diabetic Retinopathy Study [ETDRS] lines), and no eye experienced worsening of visual acuity (>= 2 ETDRS lines). Mean baseline BCVA was 20/200 (0.96 logarithm of the minimum angle of resolution [logMAR] units), and the mean 12-month BCVA was 20/80 (0.62 logMAR units; P<0.0001). Optical coherence tomography demonstrated that mean CMT at baseline was 499.9 mu m (range, 298-784 mu m) and decreased to a mean of 286.1 mu m (range, 168-499 mu m) at 12 months (P<0.0001). Four (11%) eyes received 2 injections, 10 (27.8%) eyes received 3 injections, 10 (27.8%) eyes received 4 injections, 1 (2.8%) eye received 5 injections, and 1 (2.8%) eye received 6 injections. the mean number of injections was 2.7 (range, 1-6), and the mean interval between injections was 15.1 weeks (range, 4-45 weeks). No ocular or systemic adverse events were observed.Conclusions: Short-term results suggest that IVT bevacizumab is well tolerated in patients with refractory pseudophakic CME. Treated eyes had a significant improvement in BCVA and decrease in macular thickness by OCT at 12 months.Financial Disclosure(s): the author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2009;116:1481-1487 0 2009 by the American Academy of Ophthalmology.
ISSN: 0161-6420
Other Identifiers:
Appears in Collections:Em verificação - Geral

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.